volociximab (M200) / AbbVie, Biogen - LARVOL DELTA

Integrin α5β1 in pancreatic ductal adenocarcinoma: Tumour‒stroma crosstalk, hypoxia and therapeutic targeting. (PubMed, Clin Transl Med) - "Integrin α5β1 is a biologically relevant therapeutic target for modulating the fibrotic stroma and overcoming treatment resistance in PDAC, and it may also be implicated in tumorstroma crosstalk within the hypoxic microenvironment. Successful clinical translation of α5β1-targeted strategies will likely require further mechanistic investigation, biomarker-guided patient selection, and rational combination approaches to address pathway redundancy and the limited efficacy of monotherapy."

Journal • Review • Fibrosis • Immunology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • ITGA5

TROP2 promotes bone metastasis of colorectal cancer through interaction with the fibronectin-integrin axis. (PubMed, Cell Mol Life Sci) - "TROP2 promotes CRC bone metastasis by interacting with bone marrow-derived FN-integrin axis. Through its adhesive function, TROP2 may coordinate with the specialized bone niche to facilitate metastatic colonization and establish a permissive environment for stromal-tumor interactions. Targeting this axis offers a promising therapeutic strategy for managing bone metastasis in CRC and potentially other TROP2-overexpressing malignancies."

Journal • Colorectal Cancer • Oncology • Solid Tumor • FN1 • TACSTD2

RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis. (PubMed, Mol Biomed) - "Notably, combined treatment with lenvatinib and either the ITGA5 inhibitor volociximab or the FAK inhibitor defactinib effectively reversed lenvatinib resistance in preclinical models. Furthermore, clinical analyses revealed that elevated expression of RPRD1A and ITGA5 correlates with poor response to lenvatinib in HCC patients, reinforcing their potential as predictive biomarkers for therapeutic resistance. Collectively, our results demonstrate that co-targeting the RPRD1A-ITGA5-FAK signaling axis in combination with lenvatinib represents a promising strategy to improve therapeutic efficacy in HCC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • ITGA5 • JUN

NephroAIX: Large Language Model (LLM)-Guided Knowledge Graph for Explainable Target Discovery in Human Kidney Diseases Using Single-Cell Data (KIDNEY WEEK 2025) - "LUCITANIB, a multi-kinase inhibitor targeting growth factor receptors VEGFRs and FGFRs, and VESENCUMAB, a monoclonal antibody inhibiting VEGFR-2 were identified as top repurposing candidates to target FGFR-NPR1 axis in AKI. For CKD, we found ATN-161, a peptide antagonist of integrin α5β1, a receptor involved in cell-matrix adhesion, inflammation, and fibrosis, and VOLOCIXIMAB, a chimeric monoclonal antibody that targets integrin α5β1 as two drugs associated with immune-podocyte interactions...Integrating AI with multi-modal single-cell omics holds immense potential to identify novel targets, elucidate disease pathways, and accelerate drug discovery. This synergy paves the way for precision nephrology, transforming how kidney diseases are understood and treated."

Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Nephrology • Novel Coronavirus Disease • Renal Disease • CXADR • FGFR

Inside a Metastatic Fracture: Molecular Bases and New Potential Therapeutic Targets. (PubMed, Cancer Med) - "This paper underscores the importance of advanced molecular biology and transcriptomics in identifying novel therapeutic targets. The integration of these biomarkers with clinical and radiological assessments using artificial intelligence tools could revolutionize the diagnostics and treatment strategies for patients with bone metastases."

Biomarker • Journal • Review • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Diseases • Oncology • Orthopedics • Solid Tumor • ISLR • TNFRSF11B

Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. (PubMed, Oncogene) - "In this respect, M200 decreased human osteoclast-mediated bone resorption in vitro. Overall, this study identifies ITGA5 as a mediator of breast-to-bone metastasis and raises the possibility that volociximab/M200 could be repurposed for the treatment of ITGA5-positive breast cancer patients with bone metastases."

Journal • Breast Cancer • Oncology • Solid Tumor • FN1 • ITGA5

Protein-driven mechanism of multiorgan damage in COVID-19. (PubMed, Med Drug Discov) - "After removal of drugs having undesirable drug-drug interactions we select 7 drugs and one natural product: apabetalone, romidepsin, silmitasertib, ozanezumab, procaine, azacitidine, amlexanox, volociximab, and ellagic acid, whose combinations can palliate the organs and systems found to be damaged by COVID-19. We found that at least 4 drugs are needed to treat all the multiorgan damages, for instance: the combination of romidepsin, silmitasertib, apabetalone and azacitidine."

Journal • Cardiovascular • Dermatology • Gastrointestinal Disorder • Infectious Disease • Musculoskeletal Diseases • Novel Coronavirus Disease